Шестдесет и три пациента са получили начална доза от 50 mg SUTENT перорално веднъж дневно в
Cytokine-Refractory Metastatic Renal Cell Carcinoma A phase 2 study of SUTENT was conducted in patients who were refractory to prior cytokine therapy with interleukin-2 or interferon-α.